Tailing Pharmaceutical (01011) announced interim results. Shareholders should have accounted for losses of 18.433 million yuan, an increase of 9.03% over the previous year

According to the Zhitong Finance App, Tailing Pharmaceutical (01011) announced the 2026 interim results. The group achieved revenue of 236.65 million yuan, an increase of 97.29% over the previous year; the loss due to the company owner was 18.433 million yuan, an increase of 9.03% over the previous year; and a loss of 2.24 points per share.

At present, the Group has built a multi-dimensional collaborative business matrix: the core treatment segment is anchored by specialized distribution and marketing of the innovative orthopedic drug “teriparatide”, complemented by unique traditional Chinese medicine and health products for bone health, forming a stable business foundation. Based on this, the Group strategically expanded diagnostic services through the acquisition of artificial intelligence bone health diagnostic robots. These smart devices use artificial intelligence algorithms to achieve efficient and accurate screening of bone density and bone health risks, filling the Group's business gap in early bone health screening.